Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534604 | 0.80 | CYP2C8 (0.36) | CYP2C8DAOSLC6A4 | |
| SCHEMBL28783294 | 0.73 | LOXL2 (0.39) | CSNK2A1 | |
| SCHEMBL21736824 | 0.72 | CYP2C8 (0.36) | CYP2C8DAOBACE1 | |
| SCHEMBL533923 | 0.71 | MTNR1A (0.48) | — | |
| SCHEMBL31099061 | 0.71 | HTR1A (0.40) | SLC6A4 | |
| SCHEMBL898226 | 0.71 | HTR1A (0.40) | SLC6A4 | |
| SCHEMBL17157472 | 0.69 | PTPRC (0.40) | CSNK2A1BACE1 | |
| SCHEMBL15716257 | 0.69 | MAOB (0.36) | SLC6A4 | |
| SCHEMBL2794148 | 0.69 | CSNK2A1 (0.40) | CSNK2A1 | |
| SCHEMBL4858 | 0.68 | TAAR1 (0.47) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | CYP2C8 344/4885CSNK2A1 4458/4885DAO 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.